{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:23:27Z","timestamp":1792628607893,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.thromres.2018.01.013","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T12:49:46Z","timestamp":1515415786000},"page":"6-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1274-6446","authenticated-orcid":false,"given":"K.K.","family":"Utne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.P.","family":"Jelsness-J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Sandset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ghanima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2018.01.013_bb0005","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11239-009-0309-3","article-title":"Incidence and cost burden of post-thrombotic syndrome","volume":"28","author":"Ashrani","year":"2009","journal-title":"J. Thromb. Thrombolysis"},{"issue":"3","key":"10.1016\/j.thromres.2018.01.013_bb0010","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2009.07601.x","article-title":"Post-thrombotic syndrome: prevalence, prognostication and need for progress","volume":"145","author":"Prandoni","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.013_bb0015","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1365-2141.2006.06200.x","article-title":"The post-thrombotic syndrome: progress and pitfalls","volume":"134","author":"Kahn","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.013_bb0020","first-page":"27","article-title":"Quality of life in venous disease","volume":"90","author":"van Korlaar","year":"2003","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2018.01.013_bb0025","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1538-7836.2008.03002.x","article-title":"Determinants of health-related quality of life during the 2\u202fyears following deep vein thrombosis","volume":"6","author":"Kahn","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2018.01.013_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002984","article-title":"Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study","volume":"3","author":"Enden","year":"2013","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.thromres.2018.01.013_bb0035","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1538-7836.2005.01333.x","article-title":"Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome","volume":"3","author":"van Dongen","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2018.01.013_bb0040","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1111\/j.1538-7836.2012.04872.x","article-title":"Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study","volume":"10","author":"Chitsike","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.013_bb0045","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/1076029613481845","article-title":"Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac\/noniliac venous thrombosis: a subanalysis from the home-LITE study","volume":"19","author":"Hull","year":"2013","journal-title":"Clin. Appl. Thromb. Hemost."},{"issue":"8","key":"10.1016\/j.thromres.2018.01.013_bb0050","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.amjmed.2011.02.033","article-title":"Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review","volume":"124","author":"Hull","year":"2011","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.013_bb0055","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-0609.2011.01733.x","article-title":"Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants","volume":"88","author":"Prandoni","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"9810","key":"10.1016\/j.thromres.2018.01.013_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)61753-4","article-title":"Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial","volume":"379","author":"Enden","year":"2012","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.thromres.2018.01.013_bb0065","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.013_bb0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11239-007-0108-7","article-title":"New oral Xa and IIa inhibitors: updates on clinical trial results","volume":"25","author":"Haas","year":"2008","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.thromres.2018.01.013_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"24","key":"10.1016\/j.thromres.2018.01.013_bb0080","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.thromres.2018.01.013_bb0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.thromres.2018.01.013_bb0090","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.thromres.2018.01.013_bb0095","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.013_bb0100","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/jth.13569","article-title":"The postthrombotic syndrome: current evidence and future challenges","volume":"15","author":"Rabinovich","year":"2017","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.013_bb0105","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1160\/th15-04-0318","article-title":"Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome","volume":"115","author":"Utne","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.013_bb0110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol","year":"1990","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.013_bb0115","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"issue":"2","key":"10.1016\/j.thromres.2018.01.013_bb0120","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1067\/mva.2003.152","article-title":"Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life","volume":"37","author":"Lamping","year":"2003","journal-title":"J. Vasc. Surg."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.013_bb0125","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1471-6712.2008.00618.x","article-title":"Assessing burden of illness following acute deep vein thrombosis: data quality, reliability and validity of the Norwegian version of VEINES-QOL\/Sym, a disease-specific questionnaire","volume":"23","author":"Enden","year":"2009","journal-title":"Scand. J. Caring Sci."},{"issue":"6","key":"10.1016\/j.thromres.2018.01.013_bb0130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"Hansson","year":"2000","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.013_bb0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.013_bb0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/1403494809105286","article-title":"Danish EQ-5D population norms","volume":"37","author":"Sorensen","year":"2009","journal-title":"Scand. J. Public Health"},{"key":"10.1016\/j.thromres.2018.01.013_bb0145","series-title":"Modelling Danish EuroQol (EQ-5D) Tariffs by Applying the Time Trade-off Method Health Economics Papers","first-page":"4","author":"Wittrup-Jensen","year":"2008"},{"issue":"4","key":"10.1016\/j.thromres.2018.01.013_bb0150","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jvs.2008.05.033","article-title":"Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: comparative study of enoxaparin versus coumarin","volume":"48","author":"Gonzalez-Fajardo","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.thromres.2018.01.013_bb0155","series-title":"A Two-step Approach for Transforming Continuous Variables to Normal: Implications and Recommendations for IS Research","first-page":"4","volume":"28","author":"Templeton","year":"2011"},{"issue":"10","key":"10.1016\/j.thromres.2018.01.013_bb0160","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/archinte.165.10.1173","article-title":"Prospective evaluation of health-related quality of life in patients with deep venous thrombosis","volume":"165","author":"Kahn","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.013_bb0165","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s40064-016-2949-z","article-title":"Health-related quality of life after deep vein thrombosis","volume":"5","author":"Utne","year":"2016","journal-title":"Spring"},{"issue":"4","key":"10.1016\/j.thromres.2018.01.013_bb0170","first-page":"733","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis","volume":"116","author":"Cheung","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.01.013_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2017.03.022","article-title":"Recanalization rate in patients with proximal vein thrombosis treated with the direct oral anticoagulants","volume":"153","author":"Prandoni","year":"2017","journal-title":"Thromb. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T22:49:42Z","timestamp":1533077382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818300136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":35,"alternative-id":["S0049384818300136"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.013","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}